Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$2.50
+2.3%
$3.05
$1.69
▼
$5.17
$327.64M3.162.67 million shs3.63 million shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$308.58
-2.3%
$322.48
$203.35
▼
$382.54
$9.14B0.56325,435 shs286,633 shs
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$0.07
$0.07
$0.06
▼
$0.77
$30.66M1.38.10 million shsN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$48.13
-4.4%
$45.43
$38.02
▼
$61.76
$5.87B0.781.48 million shs2.08 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-1.21%-11.91%-22.78%-39.00%-2.40%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+0.15%+3.32%-2.95%-8.88%+54.74%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
0.00%0.00%0.00%0.00%-81.13%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
+4.94%+16.71%+21.78%-10.85%+26.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$2.50
+2.3%
$3.05
$1.69
▼
$5.17
$327.64M3.162.67 million shs3.63 million shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$308.58
-2.3%
$322.48
$203.35
▼
$382.54
$9.14B0.56325,435 shs286,633 shs
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$0.07
$0.07
$0.06
▼
$0.77
$30.66M1.38.10 million shsN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$48.13
-4.4%
$45.43
$38.02
▼
$61.76
$5.87B0.781.48 million shs2.08 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-1.21%-11.91%-22.78%-39.00%-2.40%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+0.15%+3.32%-2.95%-8.88%+54.74%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
0.00%0.00%0.00%0.00%-81.13%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
+4.94%+16.71%+21.78%-10.85%+26.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.57
Moderate Buy$8.50240.68% Upside
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2.93
Moderate Buy$375.0021.53% Upside
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
1.67
Reduce$10.0013,413.51% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
2.82
Moderate Buy$69.5044.40% Upside

Current Analyst Ratings Breakdown

Latest KRYS, SGMO, CCCC, and SRRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
DowngradeOutperform ➝ Peer Perform
11/10/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Reiterated RatingStrong-Buy
11/6/2026
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Initiated CoverageBuy$7.00 ➝ $6.00
11/4/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
DowngradeBuy (B) ➝ Buy (B-)
11/3/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Lower Price TargetBuy$416.00 ➝ $412.00
11/3/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Lower Price TargetBuy$403.00 ➝ $380.00
11/3/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Lower Price TargetOutperform$400.00 ➝ $375.00
11/2/2026
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
DowngradeStrong-Buy ➝ Hold
10/28/2026
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
Initiated CoverageBuy$11.00
10/23/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
UpgradeBuy (B-) ➝ Buy (B)
10/23/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
DowngradeHold ➝ Strong Sell
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$35.95M9.11N/AN/A$1.74 per share1.43
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$389.13M23.50$7.13 per share43.26$48.44 per share6.37
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$39.55M0.78N/AN/A($0.04) per share-1.85
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/A$1.38 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$104.99M-$0.72N/AN/AN/A-282.22%-37.71%-26.42%N/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$204.83M$7.3741.8734.63N/A47.91%17.02%15.48%N/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
-$122.93M-$0.38N/AN/AN/A-310.81%-2,662.06%-132.12%N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$377.94M-$3.36N/AN/AN/AN/A-175.27%-86.66%N/A

Latest KRYS, SGMO, CCCC, and SRRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.8472-$0.81+$0.0372-$0.81$0.30 million$0.57 million
11/5/2026Q3 2026
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.1945-$0.16+$0.0345-$0.16$8.52 million$8.47 million
11/2/2026Q3 2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.79$2.05+$0.26$2.05$125.77 million$127.34 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/A
5.17
5.17
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
7.89
7.53
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
N/A
0.84
0.84
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
1.16
5.41
5.40

Institutional Ownership

CompanyInstitutional Ownership
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
78.81%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
56.92%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%

Insider Ownership

CompanyInsider Ownership
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
5.60%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.10%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
4.10%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
10.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
104131.32 million123.96 millionOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
29529.63 million25.75 millionOptionable
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
480414.29 million397.29 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
289122.00 million109.44 millionOptionable

Recent News About These Companies

J.P. Morgan Remains a Buy on Scholar Rock Holding (SRRK)
Scholar Rock (NASDAQ:SRRK) Stock Rating Lowered by Wolfe Research
HC Wainwright Boosts Earnings Estimates for Scholar Rock
HC Wainwright Predicts Scholar Rock Q1 Earnings
HC Wainwright Weighs in on Scholar Rock Q1 Earnings
Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript
Scholar Rock Q3 revenue widens to $107.2 million
What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

C4 Therapeutics stock logo

C4 Therapeutics NASDAQ:CCCC

$2.50 +0.06 (+2.25%)
Closing price 03:58 PM Eastern
Extended Trading
$2.46 -0.04 (-1.44%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$308.58 -7.25 (-2.29%)
Closing price 03:59 PM Eastern
Extended Trading
$308.68 +0.10 (+0.03%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Sangamo Therapeutics stock logo

Sangamo Therapeutics NASDAQ:SGMO

$0.07 0.00 (0.00%)
As of 11/6/2026

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$48.13 -2.24 (-4.45%)
Closing price 03:58 PM Eastern
Extended Trading
$46.70 -1.43 (-2.97%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.